<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Properties of neuromuscular blocking agents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Properties of neuromuscular blocking agents</h1>
<div class="graphic"><div class="figure"><div class="ttl">Properties of neuromuscular blocking agents</div><div class="cntnt"><table cellspacing="0"><colgroup span="8" width="12%"></colgroup> <tbody> <tr> <td class="subtitle1_left">Agent</td> <td class="subtitle1_left">Vecuronium</td> <td class="subtitle1_left">Rocuronium</td> <td class="subtitle1_left">Pancuronium<sup>*</sup></td> <td class="subtitle1_left">Mivacurium<sup>¶</sup></td> <td class="subtitle1_left">Atracurium</td> <td class="subtitle1_left">Cisatracurium</td> <td class="subtitle1_left">Succinylcholine</td> </tr> <tr> <td>Type (structure)</td> <td>Non-depolarizing</td> <td>Non-depolarizing</td> <td>Non-depolarizing</td> <td>Non-depolarizing</td> <td>Non-depolarizing</td> <td>Non-depolarizing</td> <td>Depolarizing</td> </tr> <tr class="highlight_lght_gray_text"> <td>Type (duration)</td> <td>Intermediate</td> <td>Intermediate</td> <td>Long</td> <td>Short</td> <td>Intermediate</td> <td>Intermediate</td> <td>Ultrashort</td> </tr> <tr> <td>Potency – ED<sub>95</sub> (mg/kg)</td> <td>0.04</td> <td>0.3</td> <td>0.07</td> <td>0.08</td> <td>0.21</td> <td>0.04 to 0.05</td> <td>0.25 to 0.3</td> </tr> <tr class="highlight_lght_gray_text"> <td>Intubating dose (mg/kg)</td> <td>0.1 to 0.2<sup>Δ</sup></td> <td>0.6 to 1 (1.2 with RSII dose)<sup>◊</sup></td> <td>0.08 to 0.12</td> <td>0.2</td> <td>0.5 to 0.6</td> <td>0.15 to 0.2<sup>§</sup></td> <td>0.6 to 1.5</td> </tr> <tr> <td>Onset time (min)</td> <td>3 to 4</td> <td>1 to 2</td> <td>2 to 3</td> <td>3 to 4</td> <td>3 to 5</td> <td>4 to 6</td> <td>1</td> </tr> <tr class="highlight_lght_gray_text"> <td>Time to 25% recovery (min)</td> <td>20 to 35</td> <td>30 to 50 (60 to 80 with RSII dose)</td> <td>60 to 120</td> <td>15 to 20</td> <td>20 to 35</td> <td>30 to 60</td> <td>5 to 10</td> </tr> <tr> <td colspan="8">Elimination half-life (min)</td> </tr> <tr> <td> <ul class="decimal_heading"> <li>Normal organ function</li> </ul> </td> <td>50 to 60</td> <td>60 to 100</td> <td>100 to 130</td> <td>2 to 2.5</td> <td>21</td> <td>23 to 30</td> <td>&lt;1</td> </tr> <tr> <td> <ul class="decimal_heading"> <li>Renal impairment</li> </ul> </td> <td>Mild increase</td> <td>100 to 300</td> <td>Increased ×2</td> <td>3 to 4</td> <td>21</td> <td>Mild increase</td> <td>&lt;1</td> </tr> <tr> <td> <ul class="decimal_heading"> <li>Hepatic impairment</li> </ul> </td> <td>Significant increase</td> <td>120 to 400</td> <td>Increased ×2</td> <td>3 to 6</td> <td>21</td> <td>23 to 30</td> <td>&lt;1</td> </tr> <tr class="highlight_lght_gray_text"> <td>Intermittent maintenance dose (mg/kg)<sup>¥</sup></td> <td>0.01</td> <td>0.1</td> <td>0.02</td> <td>0.1</td> <td>0.1</td> <td>0.01</td> <td>N/A</td> </tr> <tr> <td>Starting infusion dose (mcg/kg/min)<sup>‡</sup></td> <td>1 to 2</td> <td>5 to 12</td> <td>Not recommended</td> <td>5 to 8</td> <td>4 to 12</td> <td>1 to 3</td> <td> </td> </tr> <tr class="highlight_lght_gray_text"> <td>Elimination route/metabolism</td> <td>Renal 10 to 50%;<br/> hepatic 30 to 50%</td> <td>Renal 30%;<br/> hepatic 70%</td> <td>Renal 40 to 70%;<br/> hepatic 20%</td> <td>Plasma cholinesterase (70% of succinylcholine rate)</td> <td>Renal 10%;<br/> Hoffman 30%;<br/> ester hydrolysis 60%</td> <td>Hoffman 30%;<br/> ester hydrolysis 60%</td> <td>Butyrylcholinesterase (plasma cholinesterase, pseudocholinesterase)</td> </tr> <tr> <td>Active metabolites</td> <td>3-desacetyl-vecuronium</td> <td>17-desacetyl-rocuronium (minimal)</td> <td>3-OH-pancuronium; 17-OH-pancuronium</td> <td>No active metabolites</td> <td>No active metabolites</td> <td>No active metabolites</td> <td>No active metabolites</td> </tr> <tr class="highlight_lght_gray_text"> <td>Side effects</td> <td>Vagal blockade with large doses</td> <td>Minimal</td> <td>Vagal block (tachycardia), catecholamine release</td> <td>Histamine release</td> <td>Histamine release; laudanosine and acrylates production</td> <td>None</td> <td>Myalgia; bradycardia/ asystole in children or with repeated dosing; dual (phase II, competitive) block; anaphylaxis</td> </tr> <tr> <td>Contraindications (other than specific allergy)</td> <td>None</td> <td>None</td> <td>Short surgical procedures (&lt;60 min); not recommended for continuous infusion</td> <td>Pseudocholinesterase deficiency</td> <td>Hemodynamically unstable patients due to histamine release</td> <td>None</td> <td>High K<sup>+</sup>; MH; muscular dystrophy; children; receptor up-regulation settings; pseudocholinesterase deficiency</td> </tr> <tr class="highlight_lght_gray_text"> <td>Comments</td> <td>Not for prolonged ICU administration (myopathy); reversible by sugammadex; elimination half-life halved in late pregnancy; 3-desacetyl metabolite has 60% of the parent compound potency</td> <td>Pain on injection; easily reversible by sugammadex; elimination half-life prolonged in ICU patient; 17-desacetyl metabolite has 20% activity</td> <td>Significant accumulation, prone to residual block (3-OH metabolite has 50% activity of pancuronium)</td> <td>Reversal by cholinesterase inhibitors; mixture of 3 isomers (cis-cis minimal); edrophonium for antagonism more effective during deep block</td> <td>Organ-independent elimination</td> <td>Trivial histamine release; minimal plasma laudanosine and acrylate levels</td> <td>Fastest onset, most reliable NMBA for rapid tracheal intubation</td> </tr> </tbody></table></div><div class="graphic_lgnd">The data in this table are averages obtained from published literature and do not account for other influences such as the use of volatile anesthetics or muscle temperature. For further information refer to UpToDate content on clinical use of neuromuscular blocking agents.</div><div class="graphic_footnotes"><p>ED<sub>95</sub>: effective dose to achieve 95% depression of baseline muscle contraction; ICU: intensive care unit; K<sup>+</sup>: potassium; MH: malignant hyperthermia; N/A: data not available; NMBA: neuromuscular blocking agents; RSII: rapid sequence induction and intubation; ST: single twitch.</p>
<p>* Pancuronium is no longer available in the United States, Canada, or Europe. It is available in several countries around the world.</p>
<p>¶ Mivacurium is no longer available in the United States or Canada. It is available in many other countries.</p>
<p>Δ Vecuronium at a dose of 0.1 to 0.2 mg/kg may be used for RSII in patients for whom succinylcholine is contraindicated and rocuronium is unavailable; onset of paralysis will be delayed compared with those preferred agents.</p>
<p>◊ Some experts use a higher dose, 1.5 mg/kg IV, of rocuronium for rapid sequence induction in the emergency department. Refer to UpToDate content on rapid sequence in duction for emergency intubation.</p>
<p>§ Cisatracurium at a dose of 0.4 mg/kg may be used for RSII in patients for whom succinylcholine is contraindicated and rocuronium is unavailable; onset of paralysis will be delayed compared with those preferred agents.</p>
<p>¥ Intermittent dosing titrated to endpoints such as ventilator synchrony may be preferred to continuous infusions in the ICU. Higher intermittent maintenance doses may be used in the ICU to provide a longer duration of action and to avoid continuous infusion.</p>
‡ The starting infusion dose presumes that an intubating dose or a similar loading dose has been given prior to starting the infusion. The infusion dose should be adjusted thereafter based on monitoring.</div><div class="graphic_reference">Adapted from: Brull SJ. Neuromuscular blocking agents. In: Clinical Anesthesia, 8th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Wolters Kluwer, Philadelphia 2017.</div><div id="graphicVersion">Graphic 114271 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
